DURECT CORP | 2013 | FY | 3


The following table provides a summary of amounts comprising the Company’s net share of the research and development costs for POSIDUR under the agreement with Hospira (in thousands):

 

     Year Ended December 31,  
     2013      2012      2011  

Research and development expenses reimbursable by Hospira

   $ —         $ 1,968       $ 7,792   

Research and development expenses reimbursable by the Company

     —           —           —     
  

 

 

    

 

 

    

 

 

 

Net payable to Hospira

     —           —           —     
  

 

 

    

 

 

    

 

 

 

Net receivable from Hospira

   $ —         $ 1,968       $ 7,792   
  

 

 

    

 

 

    

 

 

 

us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock